What Are Blood Mutations and How Do They Affect Health?

Blood mutations are changes in the DNA of blood cells or their precursors that alter how those cells grow, function, or survive. Some are inherited from a parent and present in every cell of the body, like the mutations behind sickle cell disease. Others are acquired over a lifetime and exist only in certain blood cell lineages, accumulating quietly for decades before they cause problems. The health effects range from negligible to life-threatening, depending on which gene is hit, how many cells carry the change, and whether the mutation gives those cells a growth advantage. What makes the topic especially interesting is a discovery from the last decade: most people over 70 carry detectable blood mutations, and those mutations appear to raise the risk of heart disease, not just blood cancer.

Inherited Versus Acquired Mutations

Blood mutations fall into two broad camps. Germline mutations originate in a parent’s egg or sperm and are passed to every cell in a child’s body. These are the mutations behind classic inherited blood diseases. Somatic mutations, by contrast, arise after conception and affect only the cells descended from the one cell where the change first occurred.¹ In the blood system, somatic mutations happen in stem cells nestled inside the bone marrow. Because stem cells keep dividing throughout life, a mutation in one stem cell can eventually populate a measurable fraction of your circulating blood with its descendants. That process sits at the heart of the most talked-about blood mutation phenomenon of recent years.

Clonal Hematopoiesis and Why It Matters

Every day, your bone marrow produces hundreds of billions of blood cells. The stem cells driving that production accumulate random DNA copying errors over time, at a rate estimated around 14 base-pair substitutions per year.² Most of these errors land in stretches of DNA that do nothing important and get carried along silently. Occasionally, though, a mutation hits a gene that gives that stem cell a subtle survival or growth edge. The cell divides a bit faster, or resists signals that would normally retire it. Over years, its offspring come to represent a noticeable chunk of blood cells. Researchers call this clonal hematopoiesis.

When the expanded clone has no obvious disease attached to it, the condition is called clonal hematopoiesis of indeterminate potential, or CHIP. It is common in older adults.³ A large longitudinal study tracking over 4,000 participants for a median of 21 years found that age and sex significantly influence who develops CHIP, while traditional cardiovascular risk factors like cholesterol and blood pressure do not independently predict it.⁴ That said, several lifestyle and health factors have been linked to higher CHIP prevalence, including smoking, obesity, inflammatory conditions, premature menopause, HIV, and prior cancer treatment. Roughly 80 percent of people with CHIP have mutations concentrated in a handful of genes involved in regulating how DNA is read and maintained.⁵

The word “indeterminate” in CHIP is doing real work. It means the mutation is there, a clone is growing, but it has not caused disease yet. Most people with CHIP never develop blood cancer from it. The yearly risk of progression to a full-blown malignancy is low for any individual. But CHIP turned out to have a health consequence nobody expected when it was first described: it raises the risk of heart disease.

How Blood Mutations Drive Cardiovascular Disease

The connection between blood mutations and heart disease caught the hematology and cardiology worlds off guard. The mechanism runs through inflammation. Mutations in a gene called TET2, one of the most commonly mutated genes in CHIP, cause white blood cells to ramp up their production of inflammatory signals.⁶ Those inflammatory immune cells do not stay in the bone marrow. They circulate throughout the body and can embed in arterial plaques or the heart muscle itself.

The downstream damage goes beyond clogged arteries. Immune cells carrying CHIP mutations produce elevated levels of inflammatory molecules, particularly interleukin-1 and interleukin-6. These molecules accelerate plaque formation in blood vessels and can directly inflame the heart muscle, promoting fibrosis and reduced cardiac function even in the absence of traditional coronary artery disease.⁷ This may partly explain why some people develop heart failure without the expected risk factors. If your bone marrow is pumping out inflammatory immune cells because of a mutation acquired decades earlier, the chronic, low-grade inflammation that results can weaken the cardiovascular system steadily over time.

From Clonal Growth to Blood Cancer

CHIP sits at one end of a spectrum of increasingly serious myeloid blood disorders. Further along the spectrum lies myelodysplastic syndrome (MDS), in which blood cell production becomes disordered enough to lower blood counts and cause symptoms. Beyond MDS lies acute myeloid leukemia (AML). More than 50 genes have been found to recur in MDS, many of them the same genes that appear in CHIP but with additional mutations piled on.⁸

The transition from a relatively benign clone to a dangerous one is driven by clonal evolution. A study that tracked mutation dynamics in nearly 700 MDS patients found that as the disease progressed, the number and diversity of mutations increased. Certain mutations acquired late in the process were associated with faster progression to leukemia and shorter survival, while mutations that appear earlier in the disease tend to move more slowly.⁹ Not every clone follows this path. The vast majority of CHIP clones never acquire the additional hits needed to become cancerous. But understanding which mutations are early versus late actors helps doctors gauge how closely a patient needs to be monitored.

The blood system also generates lymphoid cancers, including lymphomas that arise from B cells. B cells have a unique vulnerability because they naturally rearrange and mutate their own DNA to produce effective antibodies. When those natural DNA-editing processes go wrong and target the wrong genes, lymphoma can result.¹⁰

Inherited Blood Disorders

Not all blood mutations are acquired with age. Some of the best-understood genetic diseases in medicine involve inherited mutations in the genes that encode hemoglobin, the oxygen-carrying protein inside red blood cells. Sickle cell disease and beta-thalassemia are both caused by mutations in the beta-globin gene.¹¹ In sickle cell disease, a single amino acid change causes hemoglobin molecules to stick together under low-oxygen conditions, distorting red blood cells into a rigid crescent shape that clogs small vessels and causes episodes of intense pain. In thalassemia, different mutations reduce or eliminate production of beta-globin chains, leading to severe anemia that can require lifelong blood transfusions.

These conditions are especially common in populations from malaria-endemic regions, because carrying one copy of certain hemoglobin mutations provides partial protection against the parasite. When two copies are inherited, the protective effect gives way to serious disease. Co-inheritance of sickle cell trait alongside beta-thalassemia mutations can produce a clinical picture as severe as sickle cell disease itself, while inheriting alpha-globin defects alongside sickle cell trait tends to soften the severity.¹²

Mutations That Affect Blood Clotting

Another category of inherited blood mutations involves the clotting system. Hemophilia A and B result from mutations that leave the blood deficient in clotting factors, causing prolonged bleeding. On the opposite end, Factor V Leiden is a mutation that makes the clotting system overactive by resisting one of the body’s natural anticoagulant mechanisms, making it the most common inherited risk factor for venous blood clots.¹³

These two mutations can even interact in unexpected ways. There is evidence that carrying Factor V Leiden alongside hemophilia partially compensates for the clotting deficiency, because the prothrombotic mutation improves thrombin generation enough to reduce bleeding symptoms. Mouse studies confirmed that hemophilic animals carrying Factor V Leiden formed clots at injury sites where hemophilic animals without it could not.¹⁴ It is a striking illustration of how two mutations, each harmful on its own in different contexts, can partially cancel each other out.

What Accelerates Acquired Blood Mutations

Aging is the dominant driver of acquired blood mutations, but external exposures can push the process faster. Cancer therapy is a particularly potent accelerator. A study tracking clonal hematopoiesis mutations before and after treatment found a more than twofold increase in TP53 mutations after patients received chemoradiation. TP53 clones were far more likely to grow after therapy than shrink, with roughly 38 percent of TP53 mutations increasing in size compared with only 5 percent that shrank. The odds of a TP53 clone expanding after chemoradiation were nearly four times higher than for other gene mutations.¹⁵ This is clinically concerning because TP53 mutations are among the most dangerous in terms of cancer progression.

The bone marrow environment itself also appears to play a selective role. Rather than mutations alone driving inflammation, a pre-existing inflammatory marrow environment may favor the expansion of mutant stem cells, creating a feedback loop where inflammation promotes mutant clones and mutant clones promote more inflammation.¹⁶ Evidence from both CHIP and early MDS shows a strong association between mutant clone expansion and an inflamed bone marrow niche.¹⁷ This chicken-and-egg dynamic complicates the search for interventions. Treating the inflammation might slow the clones, or the clones might need to be addressed before the inflammation can be tamed.

Detecting Blood Mutations

Modern sequencing technology has made it possible to detect blood mutations at very low levels, even when the mutant clone represents only one or two percent of circulating cells. This sensitivity is a double-edged sword. Cell-free DNA sequencing, which analyzes fragments of DNA floating in the bloodstream, can pick up mutations shed by tumors, but about two-thirds of mutations detected in tumor tissue were also found as low-level background mutations in normal blood cells. Most of these had very low frequencies, typically under 10 percent.¹⁸ Distinguishing a real tumor signal from a CHIP-derived background signal has become a major technical challenge in liquid biopsy for cancer.

Newer methods are being developed to push sensitivity even further. For blood cancers specifically, highly sensitive sequencing approaches now allow clinicians to track residual disease using patient-specific mutation panels, detecting whether cancer cells persist at levels far below what standard tests can find.¹⁹ The clinical payoff here is real: catching a relapse months before it becomes visible on conventional scans can change treatment timing and outcomes.

Targeting the Mutation Directly

One of the clearest success stories in mutation-targeted treatment involves chronic myeloid leukemia (CML). CML is driven by a single, well-defined mutation: a chromosomal rearrangement that creates an abnormal fusion protein called BCR-ABL, which forces white blood cells to proliferate uncontrollably. Imatinib, developed as the first molecularly targeted cancer therapy, blocks this specific protein.²⁰ The drug transformed CML from a rapidly fatal diagnosis into a manageable chronic condition for most patients.²¹ When resistance develops, newer generations of the same class of drugs can often overcome it.²²

For more aggressive blood cancers, stem cell transplantation remains a cornerstone. A meta-analysis of prospective trials in acute myeloid leukemia found that transplanting donor stem cells reduced the risk of relapse or death by about 20 percent overall. The benefit was concentrated in patients with poor-risk and intermediate-risk disease, while those classified as good-risk AML saw no survival advantage from transplant.²³ Knowing the genetic risk category, which is determined largely by which mutations a patient’s leukemia carries, is essential for deciding whether transplant is worth its considerable risks.

Gene Editing for Inherited Blood Diseases

For inherited conditions like sickle cell disease and beta-thalassemia, the most exciting recent development is gene editing. CRISPR-Cas9 technology has been used to modify patients’ own blood stem cells outside the body and transplant them back. One approach targets a gene called BCL11A, which normally suppresses the production of fetal hemoglobin in adults. By disrupting this gene’s activity in blood stem cells, researchers can reactivate fetal hemoglobin production, which compensates for the defective adult hemoglobin. Early clinical results were striking: patients with both sickle cell disease and transfusion-dependent thalassemia achieved high levels of fetal hemoglobin, became transfusion-independent, and, in the case of sickle cell disease, stopped having pain crises more than a year after treatment.²⁴

Other strategies aim to directly correct the sickle cell mutation itself in the beta-globin gene or to recreate naturally occurring genetic variants associated with high fetal hemoglobin levels. One group used CRISPR to delete a region of the beta-globin locus to mimic a naturally occurring condition called hereditary persistence of fetal hemoglobin, achieving roughly 31 percent editing efficiency and significantly increased fetal hemoglobin expression in the resulting red blood cells.²⁵ The idea of engineering a patient’s stem cells and returning them as a one-time cure represents a fundamental shift from lifelong transfusion dependence or chronic drug therapy.²⁶

Blood Mutations That Begin Before Birth

Blood mutations are not exclusively a problem of aging. Some arise during fetal development and can set the stage for childhood leukemia. Fetal blood-forming cells operate under different biological rules than adult ones, and mutations that occur during this period can produce particularly aggressive cancers that respond poorly to treatments designed for adults.²⁷ Studies have shown that the same gene fusion can produce vastly different disease outcomes depending on whether it arises in fetal or adult blood cells, suggesting that the developmental context of the cell matters as much as the mutation itself.²⁸

Fetuses with Down syndrome illustrate this vividly. Their blood stem cells accumulate about 34 extra somatic mutations compared with chromosomally normal fetuses during development.²⁹ This increased mutational burden is one reason children with Down syndrome are at substantially elevated risk for certain types of leukemia. Recognizing pediatric blood cancers as fundamentally developmental diseases, rather than scaled-down versions of adult cancers, is reshaping how researchers design therapies for them.

When Blood Mutations Trigger Autoimmunity

The relationship between somatic mutations and the immune system extends beyond cancer and heart disease. There is a growing hypothesis that somatic mutations in immune cells can contribute to autoimmune disorders. The idea is that a mutation might allow a self-reactive immune cell, one that recognizes the body’s own tissues, to escape the checkpoints that would normally eliminate it. If that cell survives and proliferates, it could sustain an autoimmune attack that would otherwise be shut down.³⁰ The evidence is still early, but the parallel with cancer biology is suggestive: in both cases, a mutation grants a cell a survival advantage that the body’s normal regulatory systems cannot overcome.

Positive Selection and the Evolutionary Angle

An analysis of blood exome data from over 200,000 individuals in the UK Biobank identified 17 new genes under positive selection in the blood system, on top of the already-known CHIP driver genes. Clones carrying mutations in these newly identified genes grew in frequency and size with age at rates comparable to the classical drivers.³¹ The sheer breadth of genes where mutations confer a growth advantage suggests that the blood system is under strong selective pressure throughout life, with mutant clones constantly competing for space in the bone marrow. This is evolution happening inside your body on a timescale of years, not generations.

Ethical Questions Around Blood Mutation Testing

As testing for blood mutations becomes cheaper and more sensitive, difficult questions arise about what to do with the results. For someone found to have CHIP, there is currently no approved drug to shrink or eliminate the clone. Knowing about it may generate anxiety without offering a clear treatment path. There are also insurance implications: a precursor condition like CHIP could theoretically be classified as a preexisting condition, affecting coverage or premiums.³² How aggressively to test, whom to tell, and what to recommend afterward are questions that clinicians and ethicists are actively working through. For now, testing for CHIP and similar precursor states is most useful in specific clinical scenarios, such as evaluating patients before cancer therapy, interpreting confusing liquid biopsy results, or monitoring individuals already at elevated risk of blood malignancies.